The operation raised €60 million, a third of which came from Sanofi, which will hold 13.9% of the company's shares.

Nawal Ouzren Chief Executive Officer to step down for personal reasons Amit Munshi, Chairman of Sensorion to assume role of Interim CEO MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Nawal Ouzren, …

Sensorion on Mar 23, 2026 reported a 12-month mean PTA gain of 14.5 dB in n=18 patients with no treatment-related SAEs, per company release and Investing.com.

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 “ ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders today announces the completion of enrollment of patients in the first cohort of the Audiogene Phase 1/2 gene therapy clinical trial. Recruitment of the first cohort (three patients) was completed as planned, with the third patient receiving an injection of SENS-501 gene therapy product in December 2024.

Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Meanwhile, clinical-stage biotechs Marea Therapeutics and Sensorion revealed their respective plans to enter the U.S. public markets.

Sensorion, a French biotech with its U.S. outpost in Cambridge, is now weighing an initial public offering in the U.S.

Sensorion, already publicly traded in France, submitted a confidential draft registration statement with the US Securities and Exchange Commission.

France's ANSM has authorized the Phase I/II HearConnex clinical trial of Sensorion's SENS-601, with patient dosing targeted for early 2027.

Sensorion secures approval for HearConnex Phase I/II study in France  Clinical Trials Arena

Sensorion Wins Fast-Track French Approval for First SENS-601 Gene Therapy Trial  TipRanks

 

La biotech française Sensorion a annoncé mettre un terme à son programme de thérapie génique visant la surdité DFNB9. Elle se concentre désormais sur la surdité causée par une mutation sur le gène GJB...

Fin septembre, Sensorion a annoncé que l’essai clinique Audiogene visant à tester l’efficacité de la thérapie génique SENS-501 pour soigner les enfants atteints d’une surdité DFNB9 avait débuté.

Looking back to May, the pharma and biotech sector saw a steady stream of senior leadership changes.